- Stocks
- Pharma & Healthcare
- Dr Agarwals Eye Hospital
Dr Agarwals Eye Hospital share price
NSE: DRAGARWQPharma & Healthcare
Dr Agarwals Eye Hospital at a glance
Dr Agarwals Eye Hospital (NSE: DRAGARWQ) closed at ₹5,025.00 on 22 Oct 2026, up 0.12% on the day. With a market capitalisation of ₹2,428 Cr, it ranks 1055th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
Its return on equity was 26.1% in FY25. Its 52-week range is ₹4,600.00 (21 Apr 2026) to ₹6,059.70 (21 May 2026); the last close is 17.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹143 Cr (+22.3% year on year) and net profit ₹23 Cr (+35.5%), on a standalone basis. Promoters held 72.67% of the company as of 30 Jun 2026; 7.67% of promoter shares were pledged.
Key numbers
- Market cap
- ₹2,428 CrRank 1055 on NSE
- Price to book
- 9.09×FY25
- EPS (TTM)
- ₹158.78to Q1 FY27
- ROE
- 26.1%FY25
- ROCE
- 16.0%FY25
- Debt to equity
- 0.46FY25
- Net profit margin
- 13.8%FY25
- Book value / share
- ₹445.98FY25
- Dividend payout
- 4.3%FY25
- 52-week high
- ₹6,059.7021 May 2026
- 52-week low
- ₹4,600.0021 Apr 2026
- RSI (14-day)
- 40
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.12% | −2.1% | −4.6% | 0.0% | — |
Dr Agarwals Eye Hospital quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹102 Cr | ₹95 Cr | ₹100 Cr | ₹117 Cr | ₹118 Cr | ₹116 Cr | ₹120 Cr | ₹143 Cr |
| Revenue YoY | +22.7% | +25.7% | +23.7% | +16.9% | +15.2% | +22.2% | +20.2% | +22.3% |
| Net profit | ₹14 Cr | ₹10 Cr | ₹16 Cr | ₹17 Cr | ₹19 Cr | ₹17 Cr | ₹16 Cr | ₹23 Cr |
| Net profit YoY | +12.4% | +10.2% | +25.0% | +22.3% | +36.5% | +66.2% | +1.6% | +35.5% |
| Net margin | 13.8% | 10.9% | 16.0% | 14.8% | 16.4% | 14.9% | 13.5% | 16.4% |
| EPS | ₹30.11 | ₹22.13 | ₹34.02 | ₹36.72 | ₹41.04 | ₹35.76 | ₹33.60 | ₹48.38 |
Dr Agarwals Eye Hospital financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹176 Cr | ₹140 Cr | ₹201 Cr | ₹268 Cr | ₹319 Cr | ₹397 Cr |
| Operating profit | ₹20 Cr | ₹6 Cr | ₹32 Cr | ₹49 Cr | ₹62 Cr | ₹71 Cr |
| Net profit | ₹14 Cr | −₹1 Cr | ₹24 Cr | ₹37 Cr | ₹46 Cr | ₹55 Cr |
| EPS (₹) | ₹29.11 | −₹3.06 | ₹51.29 | ₹78.55 | ₹98.64 | ₹116.28 |
| Cash from operations | ₹39 Cr | ₹34 Cr | ₹57 Cr | ₹70 Cr | ₹90 Cr | ₹94 Cr |
| Total debt | ₹8 Cr | ₹10 Cr | ₹21 Cr | ₹36 Cr | ₹44 Cr | ₹82 Cr |
| Shareholders' equity | ₹56 Cr | ₹55 Cr | ₹78 Cr | ₹113 Cr | ₹157 Cr | ₹210 Cr |
Dr Agarwals Eye Hospital shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 71.90% | 71.90% | 72.67% | 72.67% | 72.67% | 72.67% |
| Foreign institutions | 1.33% | 1.50% | 1.74% | 1.82% | 2.20% | 2.24% |
| Domestic institutions | 1.95% | 2.31% | 2.36% | 2.36% | 2.12% | 2.05% |
| Non-institutions | 24.83% | 24.29% | 23.23% | 23.15% | 23.00% | 23.04% |
| Promoter shares pledged | 55.45% | 55.45% | 29.26% | 29.26% | 29.26% | 7.67% |
Dr Agarwals Eye Hospital vs peers
The listed Pharma & Healthcare companies nearest to Dr Agarwals Eye Hospital by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| DPC02Dishman Pharma | — | — | — | ₹2,676 Cr | — | — |
| HIKALHikal | ₹210.01 | −0.52% | −11.8% | ₹2,589 Cr | — | — |
| DRAGARWQDr Agarwals Eye Hospital | ₹5,025.00 | +0.12% | — | ₹2,428 Cr | — | — |
| VENUSREMVenus Remedies | ₹1,796.10 | +5.00% | +293.9% | ₹2,401 Cr | 23.3 | — |
| ALEMBICLTDAlembic | ₹92.33 | +0.21% | −2.9% | ₹2,371 Cr | 7.5 | — |
| FREDUNFredun Pharmace | ₹1,376.10 | −0.35% | — | ₹2,276 Cr | 22.5 | — |
| DCALDishman Carbogen Amcis | ₹141.95 | +0.07% | −49.1% | ₹2,226 Cr | 22.8 | — |
Ask anything about Dr Agarwals Eye Hospital
Pivot answers on the live chart with evidence you can check, and tests strategies against DRAGARWQ's own history. Try: “Why has DRAGARWQ moved over the last three months?” · “Backtest a 50-day moving-average crossover on DRAGARWQ over five years” · “Compare DRAGARWQ with DPC02 on margins and valuation”
Frequently asked questions about Dr Agarwals Eye Hospital
What is the share price of Dr Agarwals Eye Hospital today?
Dr Agarwals Eye Hospital (NSE: DRAGARWQ) last closed at ₹5,025.00 on 22 Oct 2026. Its 52-week high is ₹6,059.70 and its 52-week low is ₹4,600.00.
What is the market cap of Dr Agarwals Eye Hospital?
Dr Agarwals Eye Hospital's market capitalisation is ₹2,428 Cr (₹2,428 Cr) at the 22 Oct 2026 close, ranking 1055th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Dr Agarwals Eye Hospital?
Return on equity was 26.1% in FY25 and return on capital employed was 16.0% in FY25 (standalone figures).
Is Dr Agarwals Eye Hospital a debt-free company?
No. Dr Agarwals Eye Hospital's debt-to-equity ratio was 0.46 in FY25, with total debt of ₹82 Cr.
What were Dr Agarwals Eye Hospital's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Dr Agarwals Eye Hospital reported revenue of ₹143 Cr, +22.3% year on year, and net profit of ₹23 Cr, +35.5% year on year.
What is the shareholding pattern of Dr Agarwals Eye Hospital?
As of 30 Jun 2026: promoters 72.67%, foreign institutions 2.24%, domestic institutions 2.05%, non-institutions 23.04%. 7.67% of promoter shares were pledged.
Who are Dr Agarwals Eye Hospital's competitors?
The listed Pharma & Healthcare companies closest to Dr Agarwals Eye Hospital by market cap are Dishman Pharma, Hikal, Venus Remedies, Alembic, Fredun Pharmace and Dishman Carbogen Amcis.
Is Dr Agarwals Eye Hospital a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Dr Agarwals Eye Hospital's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DRAGARWQ against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with D · all NSE stocks · this page as text